Wang Yiqing, Zhou Zhen, Broder Jonathan C, Woods Robyn L, Orchard Suzanne Gaye, Wolfe Rory, Ernst Erika J, Ryan Joanne, Ernst Michael E, Chan Andrew T
From the Clinical and Translational Epidemiology Unit (Y.W., A.T.C.), and Division of Gastroenterology (Y.W., A.T.C.), Massachusetts General Hospital and Harvard Medical School, Boston; School of Public Health and Preventive Medicine (Z.Z., J.C.B., R.L.W., S.G.O., R.W., J.R.), Monash University, Melbourne; Menzies Institute for Medical Research (Z.Z.), University of Tasmania, Australia; Department of Pharmacy Practice and Science (E.J.E.. M.E.E.), College of Pharmacy, and Department of Family Medicine (M.E.E.), Carver College of Medicine, University of Iowa, Iowa City; Department of Immunology and Infectious Diseases (A.T.C.), Harvard T.H. Chan School of Public Health, Boston; and Cancer Center (A.T.C.), Massachusetts General Hospital, Boston, MA.
Neurology. 2025 Jan 14;104(1):e210129. doi: 10.1212/WNL.0000000000210129. Epub 2024 Dec 18.
Antibiotics rapidly reduce intestinal bacterial diversity, leading to dysbiosis that persists for months to years. Although emerging evidence from retrospective and claims-based studies has linked dysbiosis to cognitive function, prospective data are lacking. We aim to examine the prospective association of antibiotics with cognitive aging among initially healthy older adults.
We leveraged data from prospective follow-up and observational extension of ASPirin in Reducing Events in the Elderly, a completed randomized trial of community-based Australian older adults. Among participants whose prescription records were available and without dementia during the first 2 years of follow-up, we identified any or repeated antibiotic use based on the Anatomical Therapeutic Chemical code (J01). We assessed the associations of antibiotic use during the first 2 years with longitudinal changes in standardized composite and domain-specific cognitive scores (global cognition, episodic memory, language and executive function, and psychomotor speed) using linear mixed models, and with incident, clinically adjudicated dementia ( criteria) and incident cognitive impairment, no dementia (CIND, without a dementia trigger but with significant, nontransient decline), using Cox proportional hazard models.
Over a median of 4.7 years after the second follow-up visit, we documented 461 dementia and 2,576 CIND cases among 13,571 participants (mean age ± SD 75.0 ± 4.1 years, 54.3% female). Compared with nonuse, antibiotic use was not associated with increased risks for dementia (hazard ratio [HR] 1.03; 95% CI 0.84-1.25), CIND (HR 1.02; 95% CI 0.94-1.11), or subsequent declines in cognitive scores, after adjusting for sociodemographic, lifestyle factors, family history of dementia, baseline cognitive function, and medications known to affect cognition. There were also no associations according to the cumulative frequency of antibiotic use, long-term use, specific antibiotic classes (e.g., beta-lactams, tetracyclines, and sulfonamides), and subgroups defined by risk factors.
Among initially healthy older adults, any or repeated antibiotic use was not associated with incident dementia, CIND, or accelerated cognitive decline. Although prescription data may not reflect the actual use, we examined the frequency of antibiotics within a defined period to capture the extent and duration of antibiotic exposure. Our results do not support an association between antibiotic-associated gut microbiome disruption and dementia risk.
抗生素会迅速降低肠道细菌多样性,导致持续数月至数年的生态失调。尽管回顾性研究和基于索赔的研究中不断有新证据表明生态失调与认知功能有关,但前瞻性数据仍很缺乏。我们旨在研究抗生素与最初健康的老年人认知衰老之间的前瞻性关联。
我们利用了“阿司匹林降低老年人事件发生率”(ASPirin in Reducing Events in the Elderly)这一已完成的澳大利亚社区老年人随机试验的前瞻性随访和观察性扩展数据。在随访的前两年中有处方记录且无痴呆症的参与者中,我们根据解剖治疗化学代码(J01)确定是否使用过任何抗生素或重复使用过抗生素。我们使用线性混合模型评估了前两年抗生素使用与标准化综合认知得分和特定领域认知得分(整体认知、情景记忆、语言和执行功能以及精神运动速度)纵向变化之间的关联,并使用Cox比例风险模型评估了其与新发的、经临床判定的痴呆症(标准)和新发的认知障碍但无痴呆症(CIND,无痴呆症诱因但有显著的、非短暂性下降)之间的关联。
在第二次随访后的中位4.7年里,我们在13571名参与者(平均年龄±标准差75.0±4.1岁,54.3%为女性)中记录了461例痴呆症和2576例CIND病例。与未使用抗生素相比,在调整了社会人口统计学、生活方式因素、痴呆症家族史、基线认知功能以及已知会影响认知的药物后,抗生素使用与痴呆症(风险比[HR]1.03;95%置信区间0.84 - 1.25)、CIND(HR 1.02;95%置信区间0.94 - 1.11)风险增加或随后认知得分下降均无关联。根据抗生素使用的累积频率、长期使用、特定抗生素类别(如β-内酰胺类、四环素类和磺胺类)以及由风险因素定义的亚组划分,也均无关联。
在最初健康的老年人中,任何抗生素使用或重复使用抗生素与新发痴呆症、CIND或认知加速衰退均无关联。尽管处方数据可能无法反映实际使用情况,但我们检查了在特定时期内的抗生素使用频率,以了解抗生素暴露的程度和持续时间。我们的结果不支持抗生素相关的肠道微生物群破坏与痴呆症风险之间存在关联。